Lifecore Biomedical, Inc., a contract development and manufacturing organization (CDMO), has finalized a series of updated commercial arrangements with its long-term commercial Hyaluronic Acid and CDMO customer, Alcon to extend and expand the existing relationship. Additionally, the company also entered into a limited waiver and amendment to its credit agreements with Alcon and with BMO to waive certain financial reporting delivery requirements. In December of 2023, Lifecore entered into a...